Published in final edited form as:

J Med Chem. 2013 May 23; 56(10): 4044–4052. doi:10.1021/jm400265k.

Biscatecholate-Monohydroxamate Mixed Ligand Siderophore-Carbacephalosporin Conjugates are Selective Sideromycin Antibiotics that Target *Acinetobacter baumannii*

Timothy A. Wencewicz and Marvin J. Miller*

Department of Chemistry and Biochemistry, 251 Nieuwland Science Hall, University of Notre Dame, Notre Dame, IN 46556, USA

Abstract

Chemical syntheses and biological evaluation of biscatecholate-monohydroxamate mixed ligand sideromycins utilizing the carbacephalosporin β -lactam antibiotic loracarbef and the fluoroquinolone antibiotic ciprofloxacin are described. The mixed ligand β -lactam sideromycin (**1b**) had remarkably selective and extremely potent antibacterial activity against the Gram negative pathogen *Acinetobacter baumannii* ATCC 17961 (MIC = 0.0078 μ M). The antibacterial activity of the β -lactam sideromycin was inversely related to the iron(III) concentration in the testing media and was antagonized by the presence of the competing parent siderophore. These data suggested that active transport of the mixed ligand β -lactam sideromycin across the outer cell membrane of *A. baumannii* via siderophore uptake pathways was responsible for the selective and potent antibacterial activity.

Keywords

drug delivery; β -lactam; sideromycin; siderophore-conjugate; antibiotic; *Acinetobacter baumannii*

INTRODUCTION

New antibacterial chemotherapies for treating multidrug resistant (MDR) Gram-negative bacterial pathogens are desperately needed.¹ The *ESKAPE* pathogens (*E. faecium*, *S. aureus*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *E. aerogenes*, *E. coli*) highlighted by the Infectious Disease Society of America (IDSA) attest to the urgency of this public health crisis as many resistant infections once limited to the hospital setting have spread to the general public.² Among these pathogens, *Acinetobacter baumannii* is being recognized as a rising class of aggressively pathogenic Gram-negative bacteria with the capacity to be MDR.³ New antibiotics to treat MDR *A. baumannii* infections are desperately needed as there are now clinical strains resistant to every known antibiotic approved for clinical use.⁴

Recent efforts for developing new antibiotic agents against *A. baumannii* have primarily focused on combination therapies with known antibiotic classes.⁵ Other nonconventional therapies applied towards treating MDR Gram-negative infections have also been explored⁶ including bacterial gene transfer,⁷ bioengineered human tissues that produce defense

*Corresponding Author: mmiller1@nd.edu; Ph: 574 631 7571; Fax: 574 631 6652. .

Supporting Information Complete list of strains, markers, and origins for microorganisms used in this work (Table S1). Complete list of antibiotic susceptibility testing data from the agar diffusion assay (Table S2). Copies of ¹H-NMR and ¹³C-NMR spectra for compounds **1a**, **1b**, **1c**, **2**, **5**, and **6**. Copies of HPLC-MS chromatograms for compounds subjected to biological testing (**1a-Fe**, **1b**, and **1c**). This material is available free of charge via the Internet at <http://pubs.acs.org>.

peptides,⁸ nitric-oxide releasing nanoparticles,⁹ phage therapy,¹⁰ photodynamic therapy,¹¹ radioimmunotherapy,¹² and gallium as an iron-mimetic.¹³ Siderophore mediated “Trojan Horse” antibiotic drug delivery has been successful at treating highly resistant Gram-negative pathogens since these antibacterial agents overcome membrane permeability barriers¹⁴ by entering cells through active transport mechanisms.¹⁵ The drastic need for new antibiotics against *A. baumannii* inspired us to revisit a mixed ligand biscatecholate-monohydroxamate siderophore carbacephalosporin conjugate (**1b**; Figure 1) shown previously by our group¹⁶ to have selective antibacterial activity against *A. baumannii*. In this work we provide insight on the mechanism of action of conjugate **1b** and show that the impressive antibacterial potency against *A. baumannii* (MIC = 0.0078 μ M) results from its active transport through siderophore transport proteins.

To date the most successful siderophore antibiotic conjugates (synthetic sideromycins¹⁷) against Gram-negative bacteria have featured β -lactam antibiotics as the warhead.¹⁸ The β -lactam antibiotics have been particularly useful in this area since their penicillin binding protein (PBP) biological targets are in the periplasm.¹⁹ This means that the siderophore only needs to smuggle the antibiotic across the outer membrane and not all the way into the cytoplasm. For this study, we designed a siderophore-fluoroquinolone conjugate (**1c**; Figure 1) with a cytoplasmic antibiotic target (DNA gyrase¹⁹) for direct comparison with the siderophore- β -lactam conjugate (**1b**).

RESULTS AND DISCUSSION

Syntheses of Siderophores and Sideromycins

The synthesis of penta-*O*-benzyl-protected siderophore **2** was accomplished using a literature protocol previously described by our group.²⁰ The iron-free (**1a**) and iron-complexed (**1a-Fe**) siderophores were synthesized as shown in Scheme 1. Palladium-catalyzed hydrogenolysis of protected siderophore **2** in MeOH gave the universally deprotected mixed ligand siderophore **1a** in excellent yield and purity after recrystallization from MeOH/Et₂O. Treatment of siderophore **1a** with Fe(acac)₃ in MeOH gave a quantitative yield of the siderophore-Fe(III) complex as a purple solid after recrystallization from MeOH/Et₂O.

The syntheses of the benzyl protected siderophore-antibiotic conjugates **5** and **6** were accomplished by coupling suitably protected antibiotics **3** and **4** to the free carboxyl terminus of protected siderophore **2** (Scheme 2). The protected antibiotics were prepared according to previously reported literature protocols.^{16, 21} Derivatization of the free amines of the carbacephalosporin β -lactam antibiotic, loracarbef, and the fluoroquinolone antibiotic, ciprofloxacin, with large molecules, including siderophores, is well tolerated and the resulting conjugates still retain affinity for the protein target in vitro.²² Carbodiimide-mediated amide formation between *O*-PNB loracarbef TFA salt **3** and protected siderophore **2** under basic conditions provided the fully protected β -lactam conjugate **5**. Similar reaction between *O*-benzyl-ciprofloxacin (**4**) and the protected siderophore **2** gave fully *O*-benzyl protected ciprofloxacin conjugate **6**.

Universal deprotection of the *O*-PNB and *O*-benzyl protecting groups from conjugate **5** was achieved using optimized hydrogenolysis conditions described for this system previously (Scheme 2).¹⁶ The deprotection proceeded in high yield as anticipated, but the tedious purification of β -lactam sideromycin **1b** reported previously¹⁶ needed to be improved to provide higher compound purity for biological studies. A new purification protocol was developed using sequential purifications by size exclusion chromatography, preparative HPLC, and recrystallization from MeOH/Et₂O to provide analytically pure material (see the **EXPERIMENTAL** section and Supporting Information for complete experimental details,

characterization data, and purity analysis). Universal deprotection of the *O*-benzyl protecting groups from conjugate **6** was achieved using conventional Pd-catalyzed hydrogenolysis conditions (Scheme 2). The fluoroquinolone sideromycin **1c** was recrystallized from MeOH/Et₂O which provided analytically pure material with no need for chromatographic purification.

Antibacterial Activity of Siderophores and Sideromycins Against ESKAPE Pathogens

The mixed ligand β -lactam sideromycin **1b** was reported previously by our group to have unexpected selective potency towards *Acinetobacter baumannii*.¹⁶ To confirm this activity, the mixed ligand siderophore **1a**, siderophore-Fe(III) complex **1a-Fe**, sideromycin **1b**, sideromycin **1c**, and control antibiotics loracarbef and ciprofloxacin were evaluated in a broth microdilution antibacterial susceptibility assay against an *ESKAPE* panel of pathogenic Gram-positive and Gram negative bacteria (Table 1). The siderophores (**1a** and **1a-Fe**) had no growth inhibiting activity (MIC values >128 μ M) against all of the organisms which was expected since the siderophores should be growth promoting factors for the bacteria. The β -lactam sideromycin **1b** gave moderate MIC values against *S. aureus* (32 μ M) and *E. coli* (8 μ M) and a selectively potent MIC value of 0.125 μ M against *A. baumannii* which was in agreement with the previously reported antibacterial data.¹⁶ The parent β -lactam antibiotic, loracarbef, displayed a much different spectrum of antibiotic activity and had no activity against *A. baumannii* (MIC value >128 μ M). The fluoroquinolone sideromycin **1c** had no antibacterial activity against all the bacterial strains tested, while the parent fluoroquinolone antibiotic, ciprofloxacin, showed the expected broad spectrum activity.

The drastic difference in the spectrum of antibacterial activity for the β -lactam sideromycin **1b** and the parent antibiotic loracarbef was the first indication that sideromycin **1b** was being transported via siderophore-uptake pathways. If sideromycin **1b** was truly entering bacterial cells via siderophore-associated pathways, then the antibacterial activity should be antagonized by the parent siderophore (**1a**) and its corresponding Fe(III) complex (**1a-Fe**).²⁴ This antagonistic effect was indeed observed in a siderophore-sideromycin antagonism assay performed on agar media. As shown in Figure 2a, the antibacterial activity of sideromycin **1b** against *A. baumannii* ATCC 17961 was antagonized at the intersection points with siderophore **1a** and its Fe(III) complex **1a-Fe**. This observation was consistent with active transport of sideromycin **1b** by *A. baumannii* into the periplasm where the β -lactam could interact with its PBP biological target and cause cell death. Interestingly, Figure 2b shows that siderophores **1a** and **1a-Fe** had no antagonistic effects on the antibiotic activity of sideromycin **1b** against *S. aureus* SG511, a Gram-positive strain of bacteria. This phenomenon was consistent with an extracellular β -lactam target in *S. aureus* where active transport into *S. aureus* cells is not required for reaching the PBP biological target.¹⁹

Antagonism of the anti-*A. baumannii* activity of sideromycin **1b** by competing siderophores²⁴ and Fe(III) supplementation^{18d, 25} was also observed using a Kirby-Bauer²⁶ agar diffusion assay²⁷ (Figure 3). As shown in Figure 3a, sideromycin **1b** produced a growth inhibition zone with a diameter of 20.6 mm in media made deficient in Fe(III) by addition of 100 μ M 2,2'-bipyridine (BIPY). As shown in Figure 3b, addition of 100 μ M FeCl₃ to the testing media reduced the diameter of the growth inhibition zone to 16.2 mm. The inverse relationship between Fe(III) availability and antibacterial potency of sideromycin **1b** against *A. baumannii* was consistent with siderophore-related active transport across the outer membrane.²⁵ Additionally, the antagonistic effects of siderophore **1a** and its Fe(III) complex **1a-Fe** were confirmed in the agar diffusion assay. As shown in Figures 3c and 3d, 1:1 molar ratios of sideromycin **1b** and siderophore **1a** or Fe(III) complex **1a-Fe**, respectively, gave

statistically reduced diameters of growth inhibition in Fe(III)-deficient media relative to **1b** alone (Figure 3a).

The results from Figure 3 are summarized graphically in Figure 4 by plotting the diameter of the growth inhibition zone on the vertical axis under the assay conditions specified by the color coded legend. Analogous experiments were performed using **1b** against a Gram-positive pathogen, *S. aureus* SG511. The activity against *S. aureus* was not significantly perturbed by varying the Fe(III) concentration in the testing media or under competition conditions with an equimolar amount of parent siderophore (**1a**) or Fe(III) complex (**1a-Fe**). These results are consistent with the lack of antagonism observed in Figure 2 and again suggest that active transport is not necessary to reach the *S. aureus* extracellular PBP target of the β -lactam warhead.¹⁹ In contrast, the testing results against *A. baumannii* (discussed previously when referring to Figure 3) show a clear dependence on Fe(III) concentration and antagonism by **1a** and **1a-Fe** consistent with active transport of **1b**.

The influence of Fe(III) concentration and competing siderophores on the antibacterial activity of sideromycin **1b** was further quantified by determining MIC values using a broth microdilution assay (Table 2). In Fe(III)-supplemented Mueller Hinton No. 2 broth media (MHII+Fe) sideromycin **1b** produced an MIC value of 0.5 μ M against *A. baumannii* while in Fe(III)-deficient media (MHII-Fe) the MIC was 0.0078 μ M. This represents a 64-fold increase in activity when going from Fe(III)-supplemented to Fe(III)-deficient conditions. When 1:1 molar mixtures of sideromycin:siderophore, **1b:1a** and **1b:1a-Fe**, were tested, MIC values of 0.031 μ M and 0.25 μ M, respectively, were recorded. These results were in agreement with data from the agar diffusion assays (Figures 3 and 4) where the siderophore Fe(III)-complex **1a-Fe** antagonized the antibacterial activity of sideromycin **1b** to a greater extent than the iron free siderophore **1a**. As expected, the antibacterial activity of sideromycin **1b** against *S. aureus* was not influenced to any great extent by the addition Fe(III) or siderophores (**1a** and **1a-Fe**) to the media.

FURTHER DISCUSSION AND PERSPECTIVE

To better understand the highly potent and selective activity of sideromycin **1b** against *A. baumannii*, it was important to consider what is known about the organism's natural use of siderophores. The complete genome sequences of six *A. baumannii* strains have recently been reported and genome analysis revealed that siderophore biosynthetic genes were present in 5 out of the 6 sequenced strains.²⁸ The strain lacking the siderophore biosynthetic genes was the only non-clinical isolate of *A. baumannii* sequenced which suggested that siderophores are an important virulence factor for *A. baumannii* during infection. So far, three biosynthetic gene clusters for unique siderophores have been identified in *A. baumannii*²⁹ and the structures of two classes of these siderophores, (pre)acinetobactin³⁰ and fimsbactins³¹ (Figure 5), have been elucidated.

Interestingly, both (pre)acinetobactin and the fimsbactins are mixed ligand siderophores containing catecholate and hydroxamate iron(III)-chelating ligands (Figure 5). Much is known about acinetobactin assembly^{30d, e} and trafficking^{30b, c}, but it is still unclear whether preacinetobactin or acinetobactin is the biologically active siderophore. The structural similarity of (pre)acinetobactin to the siderophores anguibactin, pseudomonine, vibriobactin, pyochelin, and yersiniabactin suggests that it might also form a 1:1 siderophore:iron complex with oxygen and nitrogen atoms from the catecholate, hydroxamate, oxazoline, and imidazole ring participating in iron(III) chelation.³² With this unique structural type of metal complex, it is unlikely that the synthetic mixed-ligand siderophore **1a** and sideromycin **1b** (which presumably utilize two catecholates and one hydroxamate to make a 1:1 complex

with iron) from this work share the same membrane transport system as (pre)acinetobactin in *A. baumannii*, but at this point it cannot be ruled out.

A recent publication reported the structures, biosynthetic genes, and membrane transport genes of the fimsbactins, a new class of siderophores from *A. baumannii*.³¹ The structure of the fimsbactins are remarkably similar to the synthetic mixed ligand siderophore **1a** used in this study. Both structures contain two catechols and one hydroxamic acid ligand arranged in a similar order and architecture. While no structural information is currently available, it is possible that the synthetic siderophore **1a** and sideromycin **1b** mixed ligand iron(III) complexes mimic the fimsbactin-iron(III) complexes. As a result, these siderophore iron(III) complexes might share the same uptake pathway in *A. baumannii* which could explain the high sensitivity of *A. baumannii* to the mixed ligand biscatecholate-monohydroxamate- β -lactam sideromycin **1b**. Additionally, the transcription of all the siderophore biosynthetic and transport genes in *A. baumannii* are under the genetic control of a ferric uptake regulator (Fur) protein which helps rationalize the inverse correlation of anti-*A. baumannii* activity and Fe(III) concentration observed for sideromycin **1b** in this study.^{29b} Further investigation to see if the synthetic mixed ligand biscatecholate-monohydroxamate siderophore **1a** and sideromycin **1b** utilize fimsbactin or acinetobactin transport systems in *A. baumannii* would be of great value for optimizing the therapeutic approach of siderophore-mediated antibiotic delivery described in this work.

The mixed ligand-fluoroquinolone sideromycin **1c** showed no antibacterial activity against all the strains tested (Table 1). As discussed previously, the mixed ligand- β -lactam sideromycin **1b** was transported by Gram-negative bacteria, such as *A. baumannii*, across the outer membrane into the periplasm where its PBP biological target is located. The lack of antibacterial activity of the mixed ligand-fluoroquinolone sideromycin **1c** suggested that it was never transported across the inner membrane of *A. baumannii* into the cytoplasm where the fluoroquinolone's biological target, DNA gyrase, is located. Based on the well established structure-activity relationships of the fluoroquinolone antibiotics it is unlikely that covalent modification of the ciprofloxacin warhead in conjugate **1c** diminished all ability to inhibit DNA gyrase. It is well known that the C-7 position of the fluoroquinolone scaffold is the most forgiving in terms of bulky modifications.³³ In the case of ciprofloxacin the presence of a secondary or tertiary amine is optimal, but the distal nitrogen of the piperazine unit can be alkylated or acylated and still inhibit DNA gyrase with great potency; even when derivatized with large/siderophores such as pyoverdine from *Pseudomonas aeruginosa* as proven by Abdallah and coworkers.^{22b} Based on these arguments, it is more likely that mixed ligand synthetic sideromycin **1c** was not trafficked to the cytoplasm in *A. baumannii*. This suggests that sideromycins built around mixed ligand siderophore **1a** that target Gram-negative bacteria should feature antibiotics with periplasmic targets (Figure 6).

We previously reported siderophore-fluoroquinolone conjugates based on trihydroxamate siderophores from the ferrioxamine family with selectively potent activity against Gram-positive bacteria, including *S. aureus*, able to transport ferrioxamine siderophores to the cytoplasm.³⁴ Therefore, antibiotics with cytoplasmic targets might be reserved for sideromycins that target Gram-positive bacteria (Figure 6). The problem of delivering antibacterial drugs to the cytoplasm of Gram-negative bacteria with siderophore delivery vectors remains to be solved. One general method to expand the scope of antibacterial agents available for use in siderophore-mediated drug delivery is to design new microbe triggered linker systems that selectively release the antibiotic warhead near the desired site of action.³⁵

SUMMARY AND CONCLUSIONS

New antibacterial treatments for MDR *A. baumannii* are desperately needed as strains resistant to every known antibiotic are beginning to spread.³⁻⁴ The mixed ligand siderophore- β -lactam conjugate **1b** described here represents an important new agent that kills *A. baumannii* with exceptional nanomolar potency (MIC = 0.0078 μ M) and selectivity in whole cell antibacterial assays. To evaluate the usefulness in continuing the development of sideromycin **1b** as a potential chemotherapeutic treatment for *A. baumannii* infections, the antibacterial activity against clinical MDR isolates of *A. baumannii* and efficacy in mouse infection models are currently being pursued.

EXPERIMENTAL SECTION

Materials and Instrumentation

Reactions were conducted under an atmosphere of dry argon, unless otherwise stated. All solvents and reagents were obtained from commercial sources and used without further purification, unless otherwise stated. Dichloromethane (CH_2Cl_2) was distilled from calcium hydride. Dimethylformamide (DMF) and diisopropylethylamine ($i\text{Pr}_2\text{EtN}$) were used from Acros Seal anhydrous bottles. Pentabenzyl-biscatechol-monohydroxamate siderophore **2** was prepared according to a previously described method.²⁰ Protected antibiotics **3** and **4** were prepared as described previously.^{16, 21, 34} Sorbent Technologies silica gel 60 (32-63 μ m) was used for all silica gel column chromatography purifications.

All microbiological media and liquids were sterilized before use by autoclaving at 121 °C for at least 15 min, unless otherwise stated. Distilled, deionized, and filtered water (Millipore Milli-Q Advantage A10 Water Purification System) was used to prepare all aqueous solutions and media. Luria broth (LB) was purchased from VWR. Mueller-Hinton No. 2 broth (MHII broth; cation adjusted) was purchased from Sigma-Aldrich (St. Louis, MO). Mueller Hinton No. 2 agar (MHII agar; HiMedia Laboratories) was purchased from VWR. McFarland BaSO_4 turbidity standards were purchased from bioMérieux, Inc. Sterile plastic petri dishes (145 mm $\times$ 20 mm; Greiner Bio-One) and sterile polystyrene 96-well plates (BD Falcon) used for antibacterial susceptibility testing were purchased from VWR. Ferric chloride (anhydrous, reagent grade) and 2,2'-bipyridine (reagent plus grade) were purchased from Sigma-Aldrich.

^1H -NMR and ^{13}C -NMR spectra were recorded on a 600 MHz Varian DirectDrive spectrometer and FID data was processed using ACD/ChemSketch version 10.04. Chemical shifts (δ) are reported in parts per million (ppm) and are referenced to residual solvent. Coupling constants (J) are reported in hertz (Hz).

High resolution, accurate mass measurements were obtained with a Bruker micrOTOF II electrospray ionization time-of-flight mass spectrometer in positive ion mode using direct sample injection. Sample was introduced via flow injection at a rate of 4 $\mu\text{L}/\text{min}$, and mass spectra were accumulated from 50-3000 m/z for two minutes.

HPLC-MS was performed on a Waters ZQ instrument consisting of a chromatography module Alliance HT, photodiode array detector 2996, and mass spectrometer Micromass ZQ with an MS electrospray source operated at a capillary voltage of 3.5 kV and a desolvation temperature of 300 °C. A YMC Pro C18 reverse phase column (3.0 $\times$ 50 mm) fit with a 0.5 μm precolumn frit and a YMC Pro C18 guard column (2.0 $\times$ 10 mm) was used for all analyses. Mobile phases used were 0.1% TFA in H_2O (A) and 0.1% TFA in CH_3CN (B). A gradient was formed from 5%–80% of B in 10 min, then 80%–95% of B in 2 min, and then 95%–5% of B in 3 min at a flow rate of 0.7 mL/min (total run time of 15 min).

Preparative HPLC purifications were performed on a Waters preparative binary pump system at a flow rate of 15 mL/min with UV detection at 280 nm using a YMC-Pack Pro C18 column (150 × 20 mm; 5 μm particle size) fit with a guard column. Mobile phases used were 0.1% TFA in H₂O (A) and 0.1% TFA in CH₃CN (B). A gradient was formed from 30%–60% of B over 4 min, then 60%–90% of B over 0.25 min, and was held at 90% of B for 0.75 min.

Thin layer chromatography (TLC) was performed with Al-backed Merck 60-F₂₅₄ or Al-backed Merck RP-C18 F₂₅₆ silica gel plates using a 254 nm lamp and aqueous FeCl₃ for visualization. Melting points were determined in capillary tubes using a Thomas Hoover melting point apparatus and are uncorrected. The purity of compounds tested in biological assays was evaluated by analytical HPLC and verified to be 95%, unless otherwise noted.

Preparation of Fe(III)-Supplemented and Fe(III)-Depleted Media

Iron-deficient and iron-supplemented media prep has been described previously by our group³⁴ and is summarized again here. Iron-deficient MHII broth (MHII – Fe) was prepared by adding 0.8 mL of a 1 mg/mL filter-sterilized aqueous solution of 2,2'-bipyridine to 49.2 mL of sterile MHII broth. Iron-supplemented MHII broth (MHII + Fe) was prepared by adding 0.8 mL of a freshly prepared 1 mg/mL filter sterilized aqueous solution of FeCl₃ to 49.2 mL of sterile MHII broth. Iron-deficient MHII agar (MHII – Fe) was prepared by adding 0.5 mL of a 1 mg/mL filter-sterilized aqueous solution of 2,2'-bipyridine to 34 mL of melted MHII agar with gentle mixing. Iron-supplemented MHII agar (MHII + Fe) was prepared by adding 0.5 mL of a freshly prepared 1 mg/mL filter-sterilized aqueous solution of FeCl₃ to 34 mL of melted MHII agar with gentle mixing.

MIC Determination by the Broth Microdilution Assay

Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI, formerly the NCCLS) guidelines²³ and as described previously by our group.^{27, 34} The specific details of this assay are provided in the Supporting Information.

Paper Strip Agar Diffusion Siderophore-Sideromycin Competition Assay

A general version of this assay has been described previously by our group³⁴ and the specific procedure used in this work is provided. Cultures of *S. aureus* SG511 and *A. baumannii* ATCC 17961 were grown in LB broth for 18–24 h and standard cell suspensions of 1.5 × 10⁶ CFU/mL were prepared in saline solution (0.9% NaCl) according to a 0.5 BaSO₄ McFarland Standard.³⁶ Each standardized suspension (0.1 mL) was added to 34 mL of sterile, melted MHII – Fe agar tempered to 47 °C. After gentle mixing, the inoculated agar media was poured into a sterile plastic petri dish (145 mm × 20 mm) and allowed to solidify near a flame with the lid cracked for ~30 min. Solutions of the test compounds dissolved in a 1:10 mixture of DMSO:MeOH (**1a**, **1a-Fe**, and **1b**) or sterile, distilled, and deionized H₂O (loracarbef) were prepared at the desired concentration (2.0 mM for **1a** and **1a-Fe**; 0.5 mM for **1b**; 1.0 mM and 0.1 mM for loracarbef against *A. baumannii* and *S. aureus*, respectively). Sterile filter paper strips (Whatman No. 1 Standard Grade; cut to ~1 × 8 cm) were soaked in the test compound and laid on the surface of the inoculated agar media as shown in Figure 2. The petri dishes were incubated at 37 °C for 18–24 h and then stored at rt until being photographed at the 48 h time point.

Modified Kirby-Bauer Agar Diffusion Antibiotic Susceptibility Assay

A modified Kirby Bauer agar diffusion assay was used to assess compound antibacterial activity.²⁶ Details of this assay have been reported previously by our group and can be found in the Supporting Information.^{27, 34}

Procedures for the Syntheses of Siderophores and Sideromycins

Biscatechol-monohydroxamate siderophore (1a)—Compound **2** (145.0 mg, 0.12 mmol) was dissolved in 15 mL of MeOH in an HCl-washed 25 mL round bottom flask sealed under argon. The flask was charged with 10% Pd-C (30.0 mg) and exposed to a balloon of hydrogen gas (~1 atm). Reaction progress was monitored by RP-C18 TLC (1.5:1 CH₃CN:H₂O; FeCl₃ stain) and after 26 h there was no remaining starting material (**2**). The flask was flushed with argon and the mixture was vacuum filtered through celite. Evaporation of the MeOH gave a white solid that was recrystallized from MeOH/Et₂O to provide the desired siderophore (**1a**) in 90% yield (80.5 mg, 0.11 mmol). Mp 71–73 °C (color change), 150–160 °C (dec.); ¹H-NMR (600 MHz, CD₃OD) δ 7.23–7.19 (m, 2 H), 6.94–6.90 (m, 2 H), 6.73–6.68 (m, 2 H), 3.61–3.54 (m, 2 H), 3.48–3.40 (m, 4 H), 3.38 (t, *J* = 6.2 Hz, 2 H), 3.35 (t, *J* = 6.5 Hz, 2 H), 3.12 (t, *J* = 6.7 Hz, 2 H), 2.74 (t, *J* = 6.6 Hz, 2 H), 2.67 (dt, *J* = 17.2, 6.6 Hz, 2 H), 2.58–2.53 (m, 2 H), 2.52–2.44 (m, 2 H), 1.96 (dt, *J* = 14.6, 7.2 Hz, 1 H), 1.82 (ddd, *J* = 13.2, 6.5, 6.2 Hz, 1 H), 1.75–1.54 (m, 6 H), 1.51–1.43 (m, 2 H), 1.34–1.25 (m, 2 H); HRMS-ESI (*m/z*): [M+H]⁺ calcd. for C₃₄H₄₈N₅O₁₂: 718.3294, found 718.3278. Note: The ¹³C-NMR spectrum in CD₃OD and DMSO *d*₆-shows rotamers resulting in a complex mixture of ¹³C-signals.

Biscatechol-monohydroxamate siderophore-iron(III) complex (1a-Fe)—Siderophore **1a** (10.0 mg, 0.015 mmol) and Fe(acac)₃ (5.9 mg, 0.017 mmol) were dissolved in 5 mL of MeOH. The purple solution was heated at 40 °C (oil bath temperature) for 2 h. The MeOH was removed under reduced pressure and the purple residue was dissolved in a minimal amount of MeOH and then precipitated by addition of Et₂O. The desired siderophore-iron(III) complex (**1a-Fe**) was isolated in 98% yield as a purple solid (11.5 mg, 0.015 mmol). Mp >260 °C; HRMS-ESI (*m/z*): [M+3H]⁺ calcd. for C₃₃H₄₅FeN₅O₁₂: 771.2409, found 771.2416; HPLC-MS retention time of 1.65 min. Note: The iron(III)-complex **1a-Fe** was insoluble in pure water, many common organic solvents (EtOAc, CH₂Cl₂, CHCl₃, Et₂O, CH₃CN, MeOH), and mixed water/organic solvent systems (H₂O/MeOH, H₂O/CH₃CN). The iron(III)-complex **1a-Fe** was highly soluble in DMSO, DMF, and weakly basic aqueous solutions (5% NaHCO₃ in H₂O).

Penta-O-benzyl-biscatechol-monohydroxamate-O-PNB-loracarbef conjugate (5)—The synthesis of this compound has been reported previously by a slightly different synthetic approach.¹⁶ O-PNB-loracarbef TFA salt (**3**; 208.0 mg, 0.35 mmol) was dissolved in 5 mL of anhydrous CH₂Cl₂ and the solution was cooled to 0 °C (ice bath temp.). An excess of *i*Pr₂EtN (0.40 mL, 2.3 mmol) was slowly added under argon followed directly by a catalytic amount of DMAP (7.0 mg, 0.06 mmol), a solution of benzyl-protected siderophore **2** (450.0 mg, 0.38 mmol) in 10 mL of CH₂Cl₂, and EDC-HCl (136.0 mg, 0.71 mmol), respectively. The mixture was warmed to rt and stirred overnight under dry argon. After 24 h, TLC (3% MeOH in CH₂Cl₂; FeCl₃ stain) showed no remaining starting material (**3**). The CH₂Cl₂ was evaporated under reduced pressure and the resulting oil was partitioned between 50 mL of EtOAc and 50 mL of 1 N HCl. The layers were separated and the EtOAc was washed with 25 mL of H₂O. All the aqueous layers were combined and extracted with 50 mL of EtOAc. The EtOAc layers were combined and washed with 50 mL of brine, dried over MgSO₄, gravity filtered, and concentrated under reduced pressure. This gave 650 mg of a viscous oil that was purified via silica gel column chromatography (1.25 in × 4 in silica gel; 3%–5% MeOH in EtOAc). Pure benzyl-protected mixed ligand siderophore-loracarbef

conjugate (**5**) was obtained in 52% yield as an off-white, waxy solid (302.5 mg, 0.18 mmol). Mp 70–72 °C; ¹H-NMR (600 MHz, DMSO-*d*₆) δ 9.32 (br s, 1 H), 9.11 (d, *J* = 8.5 Hz, 1 H), 8.88 (br s, 1 H), 8.82 (br s, 1 H), 8.63 (d, *J* = 7.6 Hz, 1 H), 8.27–8.21 (m, 2 H), 7.77 (br s, 1 H), 7.69 (d, *J* = 8.8 Hz, 1 H), 7.51–7.03 (m, 35 H), 6.75 (d, *J* = 10.3 Hz, 1 H), 6.66 (s, 1 H), 5.48 (d, *J* = 7.6 Hz, 1 H), 5.46–5.35 (m, 5 H), 5.20–5.08 (m, 2 H), 5.07–4.98 (m, 2 H), 4.92–4.82 (m, 2 H), 3.95–3.73 (m, 4 H), 3.59–3.47 (m, 2 H), 3.33–3.07 (m, 8 H), 2.99–2.91 (m, 2 H), 2.62 (ddd, *J* = 18.8, 12.1, 6.3 Hz, 4 H), 2.55–2.44 (m, 4 H), 2.34–2.23 (m, 2 H), 1.85–0.98 (m, 12 H); HRMS-ESI (*m/z*): [M+Na]⁺ calcd. for C₉₂H₉₆ClN₉NaO₁₇: 1656.6505, found 1656.6538. Note: The ¹³C-NMR spectrum in DMSO-*d*₆ shows rotamers resulting in a complex mixture of ¹³C-signals.

Biscatechol-monohydroxamate-loracarbef conjugate (1b)—The synthesis of this compound has been reported previously by a slightly different synthetic approach.¹⁶ Benzyl-protected conjugate **5** (209.5 mg, 0.13 mmol) was dissolved in 2.50 mL of DMF:H₂O (95/5; v/v) in an HCl-washed round bottom flask. Concentrated HCl (33.4 μL, 0.38 mmol) and 10% Pd C (41.9 mg) were added, respectively, and the flask was sealed under argon. The flask was then flushed several times with hydrogen gas using intermediate vacuum evacuations and the mixture was left stirring at rt under a balloon of hydrogen gas (~1 atm). Reaction progress was monitored by RP-C18 TLC (1.5:1 CH₃CN:H₂O; FeCl₃ stain) and after 24 h there was no remaining starting material (**5**) and a new product appeared giving a strong FeCl₃ positive test was present (*R*_f 0.78; purple with FeCl₃ stain). The flask was flushed with argon and the mixture was vacuum filtered through glass filter paper. The DMF and H₂O were removed using high vacuum rotary evaporation (~1 mm Hg) which gave 250 mg of a viscous oil. This material was purified by size exclusion chromatography (Sephadex LH20, 10.0 g; 10% MeOH in EtOAc). Several fractions of varying purity (70–90% pure by analytical HPLC) were isolated from the size exclusion column and each fraction (Fr) was recrystallized from MeOH/Et₂O to give the desired conjugate in 68% yield as off-white solids: Fr 1 (17.5 mg), Fr 2 (44.8 mg), Fr 3 (19.5 mg), Fr 4 (10.0 mg). A portion of the largest fraction (Fr 2; 30 mg) was subjected to purification by preparative HPLC (see **Materials and Instrumentation** section above for exact details of purification) where the desired compound **1b** elutes at 4.15 min. Pure fractions were lyophilized and the obtained solid was recrystallized from MeOH/Et₂O to give 15 mg of an analytically pure sample of conjugate **1b** as a white-solid used for spectral characterization and biological testing. Mp 123–125 °C (color change), 186–188 °C (dec.); ¹H NMR (600 MHz, CD₃OD) δ 7.44–7.28 (m, 5 H), 7.23–7.18 (m, 2 H), 6.94–6.90 (m, 2 H), 6.73–6.68 (m, 2 H), 5.41 (d, *J* = 8.8 Hz, 1 H), 5.36 (d, *J* = 4.7 Hz, 1 H), 3.89–3.84 (m, 1 H), 3.81 (ddd, *J* = 13.9, 7.2, 7.0 Hz, 1 H), 3.47–3.32 (m, 8 H), 3.25 (td, *J* = 13.4, 6.6 Hz, 1 H), 3.16–3.09 (m, 2 H), 2.85–2.81 (m, 2 H), 2.71–2.47 (m, 8 H), 2.43–2.36 (m, 1 H), 1.98–1.92 (m, 1 H), 1.79 (ddd, *J* = 13.6, 6.7, 6.6 Hz, 1 H), 1.76–1.68 (m, 2 H), 1.68–1.52 (m, 6 H), 1.52–1.42 (m, 2 H), 1.32–1.23 (m, 2 H); ¹³C-NMR (150 MHz, CD₃OD) δ 175.6, 175.6, 174.9, 174.9, 174.6, 174.6, 174.1, 173.9, 171.8, 171.7, 171.6, 171.6, 166.4, 163.6, 150.6, 150.5, 150.4, 150.4, 147.5, 147.5, 147.5, 147.5, 138.3, 138.2, 130.8, 130.7, 130.6, 130.2, 130.0, 129.7, 129.5, 129.4, 129.4, 129.0, 125.6, 124.7, 119.8, 119.8, 119.7, 119.7, 119.7, 118.8, 118.7, 118.7, 118.6, 116.9, 116.9, 116.8, 116.8, 74.0, 59.9, 59.7, 59.6, 54.1, 46.9, 46.9, 44.6, 40.5, 40.2, 40.0, 38.1, 37.7, 32.5, 32.2, 32.2, 31.3, 29.8, 29.8, 29.7, 29.5, 29.5, 28.9, 28.6, 27.9, 27.8, 27.2, 27.1, 26.2, 24.8, 24.7, 23.1; HRMS-ESI (*m/z*): [M+H]⁺ calcd. for C₅₀H₆₂ClN₈O₁₅: 1049.4018, found 1049.4010. HPLC-MS retention time of 5.75 min.

Penta-O-benzyl-biscatechol-monohydroxamate-O-benzyl-ciprofloxacin conjugate (6)—*O*-Benzyl-ciprofloxacin hydrochloride salt (**4**) was free based using Amberlite IR400(OH) resin in CHCl₃ for 4 h. The resulting *O*-benzyl-ciprofloxacin amine (45.0 mg, 0.11 mmol), penta-*O*-benzyl-biscatechol monohydroxamate **2** (117.0 mg, 0.10

mmol), Pr_2EtN (0.04 mL, 0.23 mmol), DMAP (3.0 mg, 0.025 mmol), and EDC-HCl (31.0 mg, 0.16 mmol) were dissolved in 5 mL of anhydrous CH_2Cl_2 , respectively. After 24 h at rt, TLC (6% MeOH in CH_2Cl_2 ; FeCl_3 stain) showed no remaining starting material **2**. The mixture was diluted with CH_2Cl_2 (35 mL), washed with H_2O (30 mL), saturated aqueous NaHCO_3 (30 mL), and brine (30 mL), dried over anhydrous MgSO_4 , filtered, and concentrated. The crude product was purified by silica gel column chromatography (1 $\times$ 5 in silica gel; 3–5% MeOH in CHCl_3) to give the desired product (**6**) in 52% yield as a clear wax (80.9 mg, 0.05 mmol). ^1H NMR (600 MHz, CDCl_3) δ 8.53–8.46 (m, 1 H), 8.36–8.18 (m, 1 H), 8.09–7.85 (m, 3 H), 7.73–7.57 (m, 1 H), 7.54–7.00 (m, 32 H), 6.97–6.51 (m, 4 H), 6.41 (d, J = 4.1 Hz, 1 H), 6.31 (br s, 1 H), 5.40–5.36 (m, 2 H), 5.17–4.96 (m, 8 H), 4.91–4.86 (m, 2 H), 3.86–3.75 (m, 2 H), 3.75–3.55 (m, 4 H), 3.51–3.35 (m, 3 H), 3.34–3.03 (m, 10 H), 2.87–2.75 (m, 2 H), 2.71–2.39 (m, 6 H), 2.16–1.90 (m, 2 H), 1.75–1.31 (m, 12 H), 1.13–1.00 (m, 2 H); ^{13}C -NMR (150 MHz, CDCl_3) δ 173.7, 173.2, 173.0, 172.3, 172.2, 172.2, 172.0, 171.7, 171.6, 171.3, 170.4, 169.7, 165.4, 165.3, 165.2, 165.1, 165.1, 165.0, 154.1, 152.4, 151.6, 151.6, 151.6, 148.3, 147.8, 146.8, 146.7, 146.5, 144.0, 137.9, 136.5, 136.3, 136.3, 136.3, 136.3, 129.1, 129.0, 128.8, 128.8, 128.8, 128.7, 128.7, 128.6, 128.6, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.2, 128.2, 128.2, 128.1, 127.9, 127.9, 127.8, 127.8, 127.8, 127.6, 127.6, 127.5, 127.3, 127.3, 127.3, 127.3, 127.0, 126.0, 124.4, 124.4, 124.3, 124.2, 123.3, 123.1, 123.1, 123.0, 122.8, 117.9, 117.7, 116.8, 116.5, 115.1, 113.4, 113.2, 110.0, 105.1, 76.4, 76.4, 76.3, 76.2, 76.1, 71.2, 71.1, 71.0, 71.0, 66.3, 50.0, 49.5, 47.2, 45.1, 41.4, 39.2, 38.9, 38.7, 38.5, 37.0, 36.9, 34.5, 31.5, 28.6, 27.2, 26.6, 26.6, 26.3, 25.9, 24.9, 23.8, 22.6, 8.1; HRMS-ESI (m/z): $[\text{M}+\text{Na}]^+$ calcd. for $\text{C}_{93}\text{H}_{99}\text{FN}_8\text{NaO}_{14}$: 1593.7157, found 1593.7155.

Biscatechol-monohydroxamate-ciprofloxacin conjugate (1c)—Penta-*O*-Benzyl-biscatechol monohydroxamate-*O*-benzyl-ciprofloxacin conjugate (**6**; 75.0 mg, 0.05 mmol) was dissolved in 8 mL of MeOH:EtOAc (3:1) in an HCl-washed, 10 mL round bottom flask sealed under argon. The flask was charged with 10% Pd-C (18.5 mg) and exposed to a balloon of hydrogen gas (~1 atm). Reaction progress was monitored by RP-C18 TLC (1.5:1 $\text{CH}_3\text{CN}:\text{H}_2\text{O}$; FeCl_3 stain) and after 24 h there was no remaining starting material (**6**) and a new product appeared giving a strong FeCl_3 positive test was present (R_f 0.44; purple with FeCl_3 stain). The flask was flushed with argon and the mixture was diluted with MeOH, vacuum filtered through celite, and concentrated under reduced pressure to give a tan film. The film was dissolved in MeOH and the product (**1c**) precipitated as a faint purple solid after addition of cold Et_2O . The desired conjugate (**1c**) was obtained in 51% yield as a faint purple solid (25.0 mg, 0.025 mmol). Mp 131–134 °C (dec.); ^1H NMR (600 MHz, CD_3OD) δ 8.74 (s, 1 H), 7.95 (d, J = 13.8 Hz, 1 H), 7.54 (br s, 1 H), 7.22–7.17 (m, 2 H), 6.89–6.85 (m, 2 H), 6.68–6.61 (m, 2 H), 3.83–3.77 (m, 4 H), 3.71 (br s, 1 H), 3.63–3.56 (m, 2 H), 3.48–3.32 (m, 12 H), 3.13 (t, J = 6.9 Hz, 2 H), 2.82 (t, J = 5.7 Hz, 2 H), 2.74–2.63 (m, 4 H), 2.48 (dt, J = 13.7, 6.8 Hz, 2 H), 1.98–1.91 (m, 2 H), 1.81 (dt, J = 14.1, 7.0 Hz, 2 H), 1.75–1.69 (m, 2 H), 1.69–1.54 (m, 4 H), 1.53–1.44 (m, 2 H), 1.40–1.34 (m, 2 H), 1.34–1.27 (m, 2 H); HRMS ESI (m/z): $[\text{M}+\text{H}]^+$ calcd. for $\text{C}_{51}\text{H}_{64}\text{FN}_8\text{O}_{14}$: 1031.4521, found 1031.4522. HPLC-MS retention time of 7.76 min. Note: The ^{13}C NMR spectrum in CD_3OD and DMSO d_6 shows rotamers resulting in a complex mixture of ^{13}C -signals.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge the use of NMR facilities provided by the Lizzadro Magnetic Resonance Research Center at The University of Notre Dame (UND) and the mass spectrometry services provided by The UND Mass

Spectrometry & Proteomics Facility (Mrs. N. Sevova, Dr. W. Boggess, and Dr. M. V. Joyce; supported by the National Science Foundation under CHE-0741793). We thank Prof. Shariar Mobashery (UND) and Dr. Sergei Vakulenko (UND) for providing the *ESKAPE* panel of bacteria and Dr. Nuno Tiago Gao Antunes for some initial antibiotic susceptibility testing. Partial funding for this work was provided by NIH grant AI054193. TAW gratefully acknowledges The UND Chemistry-Biochemistry-Biology (CBB) Interface Program funded by NIH (T32GM075762) for three years of fellowship support. TAW thanks UND Dept. of Chemistry and Biochemistry (Grace Fellowship), the Center for Environmental Science and Technology (CEST), and Bayer for additional support.

Funding Sources This work was supported in part by the NIH.

ABBREVIATIONS

acac	acetylacetone
ATCC	American Type Culture Collection
BIPY	2,2'-bipyridine
Bn	benzyl
Boc	<i>tert</i> -butoxycarbonyl
DMAP	4-dimethylaminopyridine
DMF	dimethylformamide
DMSO	dimethylsulfoxide
EDC	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
Fur	ferric uptake regulator
HPLC	high-performance liquid chromatography
HRMS	high-resolution mass spectrometry
MDR	multidrug-resistant
MHI	Mueller–Hinton media no. II
MIC	minimum inhibitory concentration
NMR	nuclear magnetic resonance
PBP	penicillin binding protein
PNB	<i>para</i> -nitrobenzyl
TFA	trifluoroacetic acid

REFERENCES

1. Fischback MA, Walsh CT. Antibiotics for emerging pathogens. *Science*. 2009; 325:1089–1093. [PubMed: 19713519]
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE Jr. Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. *Clin. Infect. Dis.* 2009; 48:1–12. [PubMed: 19035777]
- 3 (a). Visca P, Seifert H, Towner KJ. *Acinetobacter* infection - An emerging threat to human health. *IUBMB Life*. 2011; 63:1048–1054. [PubMed: 22006724] (b) Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: Emergence of a successful pathogen. *Clin. Microbiol. Rev.* 2008; 21:538–582. [PubMed: 18625687]
4. Vila J, Pachón J. *Acinetobacter baumannii* resistant to everything: What should we do? *Clin. Microbiol. Infect.* 2011; 17:955–956. [PubMed: 21722248]

- 5 (a). Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C. Colistin and rifampicin in the treatment of multidrug-resistant *Acinetobacter baumannii* infections. *J. Antimicrob. Chemother.* 2008; 61:417–420. [PubMed: 18174197] (b) Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, Wang LR, Ko WC. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant *Acinetobacter baumannii* bacteremia: Four case reports and an in vitro combination synergy study. *Pharmacotherapy.* 2007; 27:1506–1511. [PubMed: 17963460]
6. Radu Mihai M, Martinez LR. Novel therapies for treatment of multidrug-resistant *Acinetobacter baumannii* skin infections. *Virulence.* 2011; 2:97–102. [PubMed: 21321482]
7. Shankar R, He LK, Szilagy A, Muthu K, Gamelli RL, Filutowicz M, Wendt JL, Suzuki H, Dominguez M. A novel antibacterial gene transfer treatment for multidrug-resistant *Acinetobacter baumannii*-induced burn sepsis. *J. Burn Care Res.* 2007; 28:6–12. [PubMed: 17211194]
8. Thomas Virnig CL, Centanni JM, Johnston CE, He LK, Schlosser SJ, Van Winkle KF, Chen R, Gibson AL, Szilagy A, Li L, Shankar R, Allen-Hoffmann BL. Inhibition of multidrug-resistant *Acinetobacter baumannii* by nonviral expression of hCAP-18 in a bioengineered human skin tissue. *Mol. Ther.* 2009; 17:562–569. [PubMed: 19190595]
9. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, Friedman JM. Sustained release nitric oxide releasing nanoparticles: Characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. *Nitric Oxide.* 2008; 19:12–20. [PubMed: 18457680]
10. Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ. Isolation and characterization of phi AB2: A novel bacteriophage of *Acinetobacter baumannii*. *Res. Microbiol.* 2010; 161:308–314. [PubMed: 20385229]
11. Dai T, Tegos GP, Lu Z, Huang L, Zhiyentayev T, Franklin MJ, Baer DG, Hamblin MR. Photodynamic therapy for *Acinetobacter baumannii* burn infections in mice. *Antimicrob. Agents Chemother.* 2009; 53:3929–3934.
12. Dadachova E, Casadevall A. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. *Expert Opin. Drug Deliv.* 2005; 2:1075–1084. [PubMed: 16296810]
13. Antunes LC, Imperi F, Minandri F, Visca P. In vitro and in vivo antimicrobial activity of gallium nitrate against multidrug resistant *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* 2012; 56:5961–5970.
14. Vila J, Martí S, Sánchez Céspedes J. Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*. *J. Antimicrob. Chemother.* 2007; 59:1210–1215. [PubMed: 17324960]
- 15 (a). Ji C, Juárez Hernández RE, Miller MJ. Exploiting bacterial iron acquisition: siderophore conjugates. *Future Med. Chem.* 2012; 4:297–313. [PubMed: 22393938] (b) Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D. Siderophores as drug delivery agents: Application of the “Trojan Horse” strategy. *Biometals.* 2009; 22:615–624. [PubMed: 19214755]
16. Ghosh A, Ghosh M, Niu C, Malouin F, Moellmann U, Miller MJ. Iron transport mediated drug delivery using mixed ligand siderophore- β -lactam conjugates. *Chem. Biol.* 1996; 3:1011–1019. [PubMed: 9000006]
17. Braun V, Pramanik A, Gwinner T, Köberle M, Bohn E. Sideromycins: Tools and antibiotics. *Biometals.* 2009; 22:3–13. [PubMed: 19130258]
- 18 (a). Ji C, Miller PA, Miller MJ. Iron transport-mediated drug delivery: Practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. *J. Am. Chem. Soc.* 2012; 134:9898–9901. [PubMed: 22656303] (b) Flanagan ME, Brickner SJ, Manjinder L, Casavant J, Deschenes L, Finegan SM, George DM, Granskog K, Hardink JR, Huband MD, Hoang T, Lamb L, Marra A, Mitton-Fry M, Mueller JP, Mullins LM, Noe MC, O'Donnell JP, Pattavina D, Penzien JB, Schuff BP, Sun J, Whipple DA, Young J, Gootz TD. Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols. *ACS Med. Chem. Lett.* 2011:385–390. (c) Page MGP, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. *Antimicrob. Agents Chemother.* 2010; 54:2291–2302. (d) Heinisch L, Wittmann S, Stoiber T, Berg A, Ankel-Fuchs D, Möllmann U. Highly antibacterial active aminoacyl penicillin conjugates with bis-

- catecholate siderophores based on secondary diamino acids and related compounds. *J. Med. Chem.* 2002; 45:3032–3040. [PubMed: 12086488]
19. Walsh, C. Antibiotics: Actions, origins, and resistance. ASM Press; Washington, D.C.: 2003.
20. Ghosh M, Miller MJ. Synthesis and in vitro antibacterial activity of spermidine-based mixed catechol- and hydroxamate-containing siderophore-vancomycin conjugates. *Bioorg. Med. Chem.* 1996; 4:43–48. [PubMed: 8689237]
21. Jung ME, Yang EC, Vu BT, Kiankarimi M, Spyrou E, Kaunitz J. Glycosylation of fluoroquinolones through direct oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials. *J. Med. Chem.* 1999; 42:3899–3909. [PubMed: 10508438]
- 22 (a). Brochu A, Brochu N, Nicas TI, Parr TR Jr, Minnick AA Jr, Dolence EK, McKee JA, Miller MJ, Lavoie MC, Malouin F. Modes of action and inhibitory activities of new siderophore- β -lactam conjugates that use specific iron uptake pathways for entry into bacteria. *Antimicrob. Agents Chemother.* 1992; 36:2166–2175. (b) Hennard C, Truong QC, Desnottes J-F, Paris J-M, Moreau NJ, Abdallah MA. Synthesis and activities of pyoverdinin quinolone adducts: A prospective approach to a specific therapy against *Pseudomonas aeruginosa*. *J. Med. Chem.* 2001; 44:2139–2151. [PubMed: 11405651]
23. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 8th ed. Villanova, PA: 2009.
24. Pramanik A, Braun V. Albomycin uptake via a ferric hydroxamate transport system of *Streptococcus pneumoniae* R6. *J. Bacteriol.* 2006; 188:3878–3886. [PubMed: 16707680]
25. de Lorenzo, V.; Perez Martín, J.; Escolar, L.; Pesole, G.; Bertoni, G. Mode of binding of the Fur protein to target DNA: Negative regulation of iron controlled gene expression. In: Crosa, JH.; Mey, AR.; Payne, SM., editors. Iron Transport in Bacteria. ASM Press; Washington, D.C.: 2004. p. 185-196.
26. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *Am. J. Clin. Pathol.* 1966; 45:493–496. [PubMed: 5325707]
27. Wencewicz TA, Yang B, Rudloff JR, Oliver AG, Miller MJ. N-O Chemistry for antibiotics: Discovery of *N*-alkyl-*N*-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry. *J. Med. Chem.* 2011; 54:6843–6858. [PubMed: 21859126]
- 28 (a). Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, MacDonald IJ, Martin KM, Russo T, Campagnari AA, Hujer AM, Bonomo RA, Gill SR. Comparative genome sequence analysis of multidrug-resistant *Acinetobacter baumannii*. *J. Bacteriol.* 2008; 190:8053–8064. [PubMed: 18931120] (b) Iacono M, Villa L, Fortini D, Bordoni R, Imperi F, Bonnal RJ, Sicheritz-Ponten T, De Bellis G, Visca P, Cassone A, Carattoli A. Whole-genome pyrosequencing of an epidemic multidrug-resistant *Acinetobacter baumannii* strain belonging to the European clone II group. *Antimicrob. Agents Chemother.* 2008; 52:2616–2625. (c) Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, Snyder M. New insights into *Acinetobacter baumannii* pathogenesis revealed by high density pyrosequencing and transposon mutagenesis. *Genes Dev.* 2007; 21:601–614. [PubMed: 17344419] (d) Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, Dossat C, Gas S, Kreimeyer A, Lenoble P, Oztas S, Poulain J, Segurens B, Robert C, Abergel C, Claverie JM, Raoult D, Médique C, Weissenbach J, Cruveiller S. Comparative analysis of *Acinetobacter*: Three genomes for three lifestyles. *PLoS One.* 2008; 3:e1805. [PubMed: 18350144]
- 29 (a). Antunes LCS, Imperi F, Towner KJ, Visca P. Genome-assisted identification of putative iron utilization genes in *Acinetobacter baumannii* and their distribution among a genotypically diverse collection of clinical isolates. *Res. Microbiol.* 2011; 162:279–284. [PubMed: 21144895] (b) Eijkelkamp BA, Hassan KA, Paulsen IT, Brown MH. Investigation of the human pathogen *Acinetobacter baumannii* under iron limiting conditions. *BMC Genomics.* 2011; 12:126–139. [PubMed: 21342532]
- 30 (a). Yamamoto S, Okujo N, Sakakibara Y. Isolation and structure elucidation of acinetobactin, a novel siderophore from *Acinetobacter baumannii*. *Arch. Microbiol.* 1994; 162:249–254. [PubMed: 7802543] (b) Dorsey CW, Tomaras AP, Connerly PL, Tolmasky ME, Crosa JH, Actis LA. The siderophore-mediated iron acquisition systems of *Acinetobacter baumannii* ATCC 19606 and *Vibrio anguillarum* 775 are structurally and functionally related. *Microbiology.* 2004;

- 150:3657–3667. [PubMed: 15528653] (c) Mihara K, Tanabe T, Yamakawa Y, Funahashi T, Nakao H, Narimatsu S, Yamamoto S. Identification and transcriptional organization of a gene cluster involved in biosynthesis and transport of acinetobactin, a siderophore produced by *Acinetobacter baumannii* ATCC 19606. *Microbiology*. 2004; 150:2587–2597. [PubMed: 15289555] (d) Sattely ES, Walsh CT. A Latent Oxazoline Electrophile for N-O-C Bond Formation in Pseudomonine Biosynthesis. *J. Am. Chem. Soc.* 2008; 130:12282–12284. [PubMed: 18710233] (e) Wuest WM, Sattely ES, Walsh CT. Three Siderophores from One Bacterial Enzymatic Assembly Line. *J. Am. Chem. Soc.* 2009; 131:5056–5057. [PubMed: 19320483] (f) Takeuchi Y, Ozaki S, Satoh M, Mimura K-I, Hara S-I, Abe H, Nishioka H, Harayama T. Synthesis of Acinetobactin. *Chem. Pharm. Bull.* 2010; 58:1552–1553. [PubMed: 21048355]
31. Proschak A, Lubuta P, Grün P, Löhr F, Wilharm G, De Berardinis V, Bode HB. Structure and Biosynthesis of Fimsbactins A-F, Siderophores from *Acinetobacter baumannii* and *Acinetobacter baylyi*. *ChemBioChem*. 2013; 14:633–638. [PubMed: 23456955]
32. Crosa JH, Walsh CT. Genetics and Assembly Line Enzymology of Siderophore Biosynthesis in Bacteria. *Microbiol. Mol. Biol. Rev.* 2002; 66:223–249. [PubMed: 12040125]
33. Mitscher LA. Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents. *Chem. Rev.* 2005; 105:559–592. [PubMed: 15700957]
34. Wencewicz TA, Long TE, Möllmann U, Miller MJ. Trihydroxamate Siderophore-Fluoroquinolone Conjugates are Selective Sideromycin Antibiotics that Target *Staphylococcus aureus*. *Bioconjugate Chem.* 2013; 24:473–486.
- 35 (a). Ji C, Miller MJ. Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. *Bioorg. Med. Chem.* 2012; 20:3828–3836. [PubMed: 22608921] (b) Wencewicz TA, Möllmann U, Long TE, Miller MJ. Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin “Trojan Horse” antibiotics and synthetic desferridanoxamine antibiotic-conjugates. *Biometals*. 2009; 22:633–648. [PubMed: 19221879] (c) Zheng T, Bullock JL, Nolan EM. Siderophore-Mediated Cargo Delivery to the Cytoplasm of *Escherichia coli* and *Pseudomonas aeruginosa*: Syntheses of Monofunctionalized Enterobactin Scaffolds and Evaluation of Enterobactin-Cargo Conjugate Uptake. *J. Am. Chem. Soc.* 2012; 134:18388–18400. [PubMed: 23098193]
36. Murray, PR.; Baron, EJ.; Tenover, FC.; Tenover, RH. Manual of clinical microbiology. 7 ed. American Society for Microbiology; Washington, D.C.: 1999.

Figure 1. Structures of synthetic mixed ligand siderophore (**1a**) and synthetic sideromycins (**1b** and **1c**) used in this work.

Figure 2.

Agar diffusion antagonism assay for sideromycin **1b** and siderophores **1a** and **1a-Fe** tested against (a) *A. baumannii* ATCC 17961 and (b) *S. aureus* SG511. Images are not shown to actual scale.

Figure 3.

Agar diffusion antibacterial susceptibility assay for sideromycin **1b** against *A. baumannii* ATCC 17961. Growth inhibition zones for **1b** under Fe(III)-deficient conditions (MHII agar + 100 μ M BIPY) (a), for **1b** under Fe(III)-supplemented conditions (MHII agar + 100 μ M FeCl₃) (b), for a 1:1 molar mixture of **1b** and **1a** under Fe(III)-deficient conditions (c), and for a 1:1 mixture of **1b** and **1a-Fe** under Fe(III)-deficient conditions (d). Images are shown at relative, but not actual scale. Measured zone diameters are the average of three independent trials. See the Supporting Information for tabulated data (Table S2).

Figure 4.

Effect of varying Fe(III) concentrations and competing siderophores (**1a** and **1a-Fe**) on the antibacterial activity of sideromycin **1b** against *S. aureus* SG511 and *A. baumannii* ATCC 17961 in the agar diffusion assay. The vertical axis indicates the diameter of the growth inhibition zone in millimeters (average of three independent trials) and the horizontal axis indicates the test organism. See the Supporting Information for tabulated data (Table S2). ^aMHII-Fe: Mueller-Hinton agar No. 2 + 100 μ M BIPY. ^bMHII+Fe: Mueller Hinton agar No. 2 + 100 μ M FeCl₃.

Figure 5. Structures of mixed ligand siderophores (pre-acinetobactin, acinetobactin, and fimsbactin A) produced by *A. baumannii*. Catechol and hydroxamic acid iron(III)-chelating groups are shown in red.

Figure 6.

A generic trihydroxamate sideromycin selective for Gram-positive pathogens^{35a, b} and a generic mixed ligand sideromycin selective for Gram-negative pathogens (this work).

Scheme 1.

Syntheses of iron free (**1a**) and iron-bound (**1a-Fe**) mixed ligand siderophores.

a Reagents and conditions: (a) 10% Pd-C, H₂ (1 atm), MeOH, 26 h, 90%. (b) Fe(acac)₃, MeOH, 2 h, 98%.

Scheme 2.

Syntheses of mixed ligand sideromycins **1b** and **1c**.

a Reagents and conditions: (a) EDC, **3**, *i*Pr₂EtN, DMAP, CH₂Cl₂, 24 h, 52%. (b) 10% Pd-C, H₂ (1 atm), HCl (3 equiv), DMF:H₂O (95:5), 24 h, 68%. (c) EDC, **4**, *i*Pr₂EtN, DMAP, CH₂Cl₂, 24 h, 52%. (d) 10% Pd-C, H₂ (1 atm), MeOH, 24 h, 51%.

Table 1

MIC values (μM) of compounds **1a**, **1a-Fe**, **1b**, and **1c** against *ESKAPE* panel of bacteria.^{a,b}

Entry	Compound	<i>E. faecium</i> NCTC 7171	<i>S. aureus</i> SG 511	<i>K. pneumoniae</i> ATCC 700603	<i>A. baumannii</i> ATCC 17961	<i>P. aeruginosa</i> ATCC 27853	<i>E. aerogenes</i> ATCC 35029	<i>E. coli</i> ATCC 25922
1	1a	>128	>128	>128	>128	>128	>128	>128
2	1a-Fe	>128	>128	>128	>128	>128	>128	>128
3	1b	>128	32	>128	0.125	>128	>128	8
4	1c	>128	>128	>128	>128	>128	>128	>128
5	loracarbef	32	1	128	>128	>128	>128	2
6	ciprofloxacin	8	0.5	0.25	0.25	0.125	<0.015	<0.015

^aMIC values were determined using the broth microdilution method using visual end point analysis according to the CLSI guidelines.²³

^bEach compound was tested in triplicate.

Table 2

MIC values (μM) of sideromycin (**1b**) against *A. baumannii* and *S. aureus* under varying concentrations of Fe(III) and in the presence of competing siderophores (*1a* and *1a-Fe*)^{a,b}

En-try	Compound	Test Organism			
		<i>A. baumannii</i> ATCC 17961		<i>S. aureus</i> SG511	
		MHII + Fe ^c	MHII – Fe ^d	MHII + Fe	MHII – Fe
1	1b	0.5	0.0078	64	32
2	1b + 1a	nt ^e	0.0312	nt	16
3	1b + 1a-Fe	nt	0.25	nt	32

^aMIC values were determined using the broth microdilution method using visual end point analysis according to the CLSI guidelines.²³

^bEach compound was tested in triplicate.

^cMHII + Fe: Mueller-Hinton Broth No. 2 + 100 μM FeCl₃.

^dMHII – Fe: Mueller-Hinton Broth No. 2 + 100 μM BIPY.

^ent: not tested.